Ruxolitinib
Ruxolitinib is a selective, orally administered small-molecule inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), two tyrosine kinases that play central roles in cytokine signaling through the JAK/STAT pathway.
Ruxolitinib is a selective, orally administered small-molecule inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), two tyrosine kinases that play central roles in cytokine signaling through the JAK/STAT pathway. By blocking JAK1 and JAK2 activity, ruxolitinib suppresses downstream signaling through transcription factors such as STAT1 and STAT5A, thereby attenuating the aberrant cytokine-driven inflammation and cell proliferation that underlies several hematologic malignancies and immune-mediated disorders. It was among the first JAK inhibitors to receive regulatory approval and belongs to the broader class of Janus kinase inhibitors that has transformed the management of myeloproliferative neoplasms and inflammatory conditions.
Ruxolitinib is approved for the treatment of intermediate- or high-risk myelofibrosis (MF), polycythemia vera (PV) in patients who are resistant to or intolerant of hydroxyurea, and steroid-refractory acute and chronic graft-versus-host disease (GVHD). Its mechanism centers on the inhibition of JAK1 and JAK2, suppressing signaling driven by constitutively active or mutant JAK2 (including JAK2 V617F) and JAK2 gain-of-function mutations, which drive pathological activation of the JAK2/STAT3 signaling pathway and CD44/JAK2/STAT3 signaling pathway in malignant hematopoietic cells. By dampening these cascades, ruxolitinib reduces splenomegaly, alleviates disease-related symptoms, and modulates immune responses relevant to both cancer and autoimmune disease contexts.
Where the papers sit
11 papers from the last 6 months study ruxolitinib directly · updated from PubMed 9 Nov 2026
Study type 3 clinical trials · 5 observational · 1 human data · 1 preclinical · 1 unclassified
Themes 3 themes · 1 new direction
-
JAK Inhibitor Clinical Applications
Ruxolitinib is being applied across myelofibrosis, polycythemia vera, hemophagocytic lymphohistiocytosis, hypereosinophilic syndrome, and vitiligo, but the evidence remains indication-specific. Combination therapy, including selinexor or emapalumab, is being tested alongside ruxolitinib rather than replacing it. Pharmacokinetic exposure, toxicity, imaging response, and long-term prognostic models recur as ways to refine treatment. Case series and retrospective studies leave comparative efficacy and safety unresolved.
6 papers · 54.5%
-
Graft-versus-Host Disease Treatment
Ruxolitinib use is moving beyond treatment of established graft-versus-host disease toward prevention after haploidentical transplantation and topical control of chronic skin disease. Long-term follow-up supports activity in both acute and chronic disease. Low-dose prophylaxis and topical therapy seek to limit systemic exposure while preserving benefit. The remaining questions are durability, relapse prevention, and comparative safety.
3 papers · 27.3%
-
Topical JAK Therapy in Atopic Dermatitis
Topical JAK inhibition in atopic dermatitis is moving toward both system-level cost assessment and more targeted drug delivery. Budget analysis evaluates the medical costs and body-surface-area burden of topical therapy at scale. Nanoemulgel formulations aim to improve local ruxolitinib delivery and may reduce unwanted systemic exposure. Evidence remains largely preclinical for the delivery platform, leaving clinical effectiveness and economic value to be established.
2 papers · 18.2%
Ruxolitinib becomes a candidate for therapeutic drug monitoring and exposure-guided dosing
The pharmacokinetics of ruxolitinib in hematologic malignancies and immune-mediated diseases were studied prospectively, rather than treating it solely as an intervention or outcome predictor. The study found marked between-patient variability in clearance and substantial effects of CYP3A4 and dual CYP2C9/CYP3A4 inhibitors, and it explicitly evaluated exposure-response relationships for possible therapeutic drug monitoring. This changes ruxolitinib’s role from a fixed-dose therapy to a drug whose concentrations and interactions may guide individualized dosing 42338396Jun.
Papers
The 11 papers from the last 6 months that study ruxolitinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
JAK Inhibitor Clinical Applications (6)
- Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series. Clinical immunology (Orlando, Fla.) · 24 Jul 2026 PMID 42498149
- Noninvasive imaging for the evaluation of JAK inhibitors efficacy in the management of facial vitiligo. The Journal of dermatological treatment · 20 Jul 2026 PMID 42473916
- Emapalumab plus conventional therapy with or without ruxolitinib for pediatric hemophagocytic lymphohistiocytosis: a single center retrospective study. Immunologic research · 3 Jul 2026 PMID 42397658
- Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study. Clinical pharmacology and therapeutics · 24 Jun 2026 PMID 42338396
- A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib. Blood advances · 11 Jun 2026 PMID 42275537
- Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2 Jun 2026 PMID 42227656
Graft-versus-Host Disease Treatment (3)
- Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial. The Lancet. Haematology · 16 Sept 2026 PMID 42748944
- Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease. Annals of hematology · 6 Aug 2026 PMID 42560429
- Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. Haematology · 30 Jul 2026 PMID 42532067
Topical JAK Therapy in Atopic Dermatitis (2)
- Budget Impact Analysis of System-Level Costs Associated With Topical Janus Kinase Inhibitor Therapies for Moderate Atopic Dermatitis in Germany. Value in health regional issues · 28 Sept 2026 PMID 42805028
- Targeted topical delivery of Ruxolitinib-Loaded nanoemulgel for potential management of Atopic Dermatitis: An integrated in silico, in vitro, and in vivo approach. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 21 Aug 2026 PMID 42628766
By study type
Clinical trials (3)
- Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial. The Lancet. Haematology · 16 Sept 2026 PMID 42748944
- Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. Haematology · 30 Jul 2026 PMID 42532067
- Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2 Jun 2026 PMID 42227656
Observational studies and case reports (5)
- Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease. Annals of hematology · 6 Aug 2026 PMID 42560429
- Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series. Clinical immunology (Orlando, Fla.) · 24 Jul 2026 PMID 42498149
- Noninvasive imaging for the evaluation of JAK inhibitors efficacy in the management of facial vitiligo. The Journal of dermatological treatment · 20 Jul 2026 PMID 42473916
- Emapalumab plus conventional therapy with or without ruxolitinib for pediatric hemophagocytic lymphohistiocytosis: a single center retrospective study. Immunologic research · 3 Jul 2026 PMID 42397658
- Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study. Clinical pharmacology and therapeutics · 24 Jun 2026 PMID 42338396
Human data, design not indexed (1)
- A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib. Blood advances · 11 Jun 2026 PMID 42275537
Preclinical: animal, cell and lab studies (1)
- Targeted topical delivery of Ruxolitinib-Loaded nanoemulgel for potential management of Atopic Dermatitis: An integrated in silico, in vitro, and in vivo approach. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 21 Aug 2026 PMID 42628766
Unclassified: not yet indexed with MeSH (1)
- Budget Impact Analysis of System-Level Costs Associated With Topical Janus Kinase Inhibitor Therapies for Moderate Atopic Dermatitis in Germany. Value in health regional issues · 28 Sept 2026 PMID 42805028
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.